138 related articles for article (PubMed ID: 38151581)
1. Quantification of extravasation and binding of PSMA-targeted nanobubbles by modelling the second-wave phenomenon.
Chen C; Perera R; Mischi M; Kolios M; Exner A; Turco S
Mol Imaging Biol; 2024 Apr; 26(2):253-263. PubMed ID: 38151581
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic modeling of PSMA-targeted nanobubbles for quantification of extravasation and binding in mice models of prostate cancer.
Chen C; Perera R; Kolios MC; Wijkstra H; Mischi M; Exner AA; Turco S
Med Phys; 2022 Oct; 49(10):6547-6559. PubMed ID: 36049109
[TBL] [Abstract][Full Text] [Related]
3. The unique second wave phenomenon in contrast enhanced ultrasound imaging with nanobubbles.
Chen C; Perera R; Kolios MC; Wijkstra H; Exner AA; Mischi M; Turco S
Sci Rep; 2022 Aug; 12(1):13619. PubMed ID: 35948582
[TBL] [Abstract][Full Text] [Related]
4. Optimized Anti-Prostate-Specific Membrane Antigen Single-Chain Variable Fragment-Loaded Nanobubbles as a Novel Targeted Ultrasound Contrast Agent for the Diagnosis of Prostate Cancer.
Ding Y; Cao Q; Qian S; Chen X; Xu Y; Chen J; Shen H
J Ultrasound Med; 2020 Apr; 39(4):761-773. PubMed ID: 31702068
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-mediated drug-free theranostics for treatment of prostate cancer.
Perera RH; Berg FM; Abenojar EC; Nittayacharn P; Kim Y; Wang X; Basilion JP; Exner AA
bioRxiv; 2023 Sep; ():. PubMed ID: 37745586
[TBL] [Abstract][Full Text] [Related]
6. Targeted Nanobubbles Carrying Indocyanine Green for Ultrasound, Photoacoustic and Fluorescence Imaging of Prostate Cancer.
Wang Y; Lan M; Shen D; Fang K; Zhu L; Liu Y; Hao L; Li P
Int J Nanomedicine; 2020; 15():4289-4309. PubMed ID: 32606678
[TBL] [Abstract][Full Text] [Related]
7. Real time ultrasound molecular imaging of prostate cancer with PSMA-targeted nanobubbles.
Perera RH; de Leon A; Wang X; Wang Y; Ramamurthy G; Peiris P; Abenojar E; Basilion JP; Exner AA
Nanomedicine; 2020 Aug; 28():102213. PubMed ID: 32348874
[TBL] [Abstract][Full Text] [Related]
8. Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA.
Wang Y; De Leon AC; Perera R; Abenojar E; Gopalakrishnan R; Basilion JP; Wang X; Exner AA
Sci Rep; 2021 Feb; 11(1):4726. PubMed ID: 33633232
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound-mediated drug-free theranostics for treatment of prostate cancer.
Perera RH; Berg FM; Abenojar EC; Nittayacharn P; Kim Y; Wang X; Basilion JP; Exner A
Bioact Mater; 2024 May; 35():45-55. PubMed ID: 38304914
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
12. Intracellular vesicle entrapment of nanobubble ultrasound contrast agents targeted to PSMA promotes prolonged enhancement and stability
Perera RH; Abenojar E; Nittayacharn P; Wang X; Ramamurthy G; Peiris P; Bederman I; Basilion JP; Exner AA
Nanotheranostics; 2022; 6(3):270-285. PubMed ID: 35223380
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. Construction and in vitro/in vivo targeting of PSMA-targeted nanoscale microbubbles in prostate cancer.
Wang L; Li L; Guo Y; Tong H; Fan X; Ding J; Huang H
Prostate; 2013 Aug; 73(11):1147-58. PubMed ID: 23532872
[TBL] [Abstract][Full Text] [Related]
15. Magnetic polymeric nanobubbles with optimized core size for MRI/ultrasound bimodal molecular imaging of prostate cancer.
Zhu Y; Sun Y; Liu W; Guan W; Liu H; Duan Y; Chen Y
Nanomedicine (Lond); 2020 Dec; 15(30):2901-2916. PubMed ID: 33300812
[No Abstract] [Full Text] [Related]
16. Improving ovarian cancer imaging with LHRH-NBs: an experimental study.
Li W; Zhang L; Zhu Y; Zhang J; Shen L; Huang S; Fang S
Arch Gynecol Obstet; 2016 Sep; 294(3):631-8. PubMed ID: 27075493
[TBL] [Abstract][Full Text] [Related]
17. Construction of Nucleolin-Targeted Lipid Nanobubbles and Contrast-Enhanced Ultrasound Molecular Imaging in Triple-Negative Breast Cancer.
Fang K; Wang L; Huang H; Lan M; Shen D; Dong S; Guo Y
Pharm Res; 2020 Jul; 37(7):145. PubMed ID: 32666304
[TBL] [Abstract][Full Text] [Related]
18. Combined legumain- and integrin-targeted nanobubbles for molecular ultrasound imaging of breast cancer.
Mi X; Guo X; Du H; Han M; Liu H; Luo Y; Wang D; Xiang R; Yue S; Zhang Y; Tan X
Nanomedicine; 2022 Jun; 42():102533. PubMed ID: 35150904
[TBL] [Abstract][Full Text] [Related]
19. Nanobubbles as ultrasound contrast agent for facilitating small cell lung cancer imaging.
Wang JP; Zhou XL; Yan JP; Zheng RQ; Wang W
Oncotarget; 2017 Sep; 8(44):78153-78162. PubMed ID: 29100457
[TBL] [Abstract][Full Text] [Related]
20. Production and characterization of a novel long-acting Herceptin-targeted nanobubble contrast agent specific for Her-2-positive breast cancers.
Jiang Q; Hao S; Xiao X; Yao J; Ou B; Zhao Z; Liu F; Pan X; Luo B; Zhi H
Breast Cancer; 2016 May; 23(3):445-55. PubMed ID: 25691133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]